. "# Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11329054 # Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14528282 # Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP: Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004 Feb;57(2):86-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14750129 # Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-68. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12908564 # Tan AR, Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14613027 # IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=7637 # IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1N8Z # Nebija D, Kopelent-Frank H, Urban E, Noe CR, Lachmann B: Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. J Pharm Biomed Anal. 2011 Dec 5;56(4):684-91. doi: 10.1016/j.jpba.2011.07.006. Epub 2011 Jul 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21813259 #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995.Trastuzumab; [updated 2014 Nov 05; cited 2014 Nov 12.Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=2&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=233586"@en . "Humans and other mammals"@en . "Anti HER2"@en . "approved"@en . "Ig gamma-1 chain C region"@en . . . "Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells."@en . . "investigational"@en . "A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*"@en . "* 44 mL/kg"@en . . . . "180288-69-1"@en . . " "@en . "Peak and trough plasma concentrations at steady state (between weeks 16 and 32) approximately 123 and 79 mcg/mL, respectively."@en . "average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance."@en . . . "Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy."@en . . . . . . . . . "For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2."@en . "Elimination may involve clearance of IgG through the reticuloendothelial system."@en . . . . . . . . . "Trastuzumab"@en .